MiR-205 in Breast Cancer: State of the Art

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2020 Dec 30

PMID 33375067

Citations 29

Authors

Ilaria Plantamura

Alessandra Cataldo

Giulia Cosentino

Marilena V Iorio

Affiliations

Soon will be listed here.

Abstract

Despite its controversial roles in different cancer types, miR-205 has been mainly described as an oncosuppressive microRNA (miRNA), with some contrasting results, in breast cancer. The role of miR-205 in the occurrence or progression of breast cancer has been extensively studied since the first evidence of its aberrant expression in tumor tissues versus normal counterparts. To date, it is known that the expression of miR-205 in the different subtypes of breast cancer is decreasing from the less aggressive subtype, estrogen receptor/progesterone receptor positive breast cancer, to the more aggressive, triple negative breast cancer, influencing metastasis capability, response to therapy and patient survival. In this review, we summarize the most important discoveries that have highlighted the functional role of this miRNA in breast cancer initiation and progression, in stemness maintenance, in the tumor microenvironment, its potential role as a biomarker and its relevance in normal breast physiology-the still open questions. Finally, emerging evidence reveals the role of some lncRNAs in breast cancer progression as sponges of miR-205. Here, we also reviewed the studies in this field.

Citing Articles

miR-205 Regulates Tamoxifen Resistance by Targeting Estrogen Receptor Coactivator MED1 in Human Breast Cancer.

Ouyang B, Bi M, Jadhao M, Bick G, Zhang X Cancers (Basel). 2024; 16(23.

PMID: 39682180 PMC: 11640040. DOI: 10.3390/cancers16233992.

Evaluation of tumorigenesis-related miRNAs in breast cancer in Egyptian women: a retrospective, exploratory analysis.

Salum G, Elaraby N, Ahmed H, Abd El Meguid M, Fotouh B, Ashraf M Sci Rep. 2024; 14(1):29757.

PMID: 39614097 PMC: 11607072. DOI: 10.1038/s41598-024-68758-0.

Modulation of miR-205 expression using a phyto-nano hybrid as a potential therapeutic agent against breast cancer.

Razzaq F, Shahid S, Shahid W RSC Adv. 2024; 14(50):37286-37298.

PMID: 39575377 PMC: 11580155. DOI: 10.1039/d4ra03069a.

An ultrasensitive electrochemical biosensor with dual-amplification mode and enzyme-deposited silver for detection of miR-205-5p.

Xie X, Chen C, Chen W, Qin Y, Xiang S, Jiang J Mikrochim Acta. 2024; 191(9):545.

PMID: 39158763 DOI: 10.1007/s00604-024-06596-7.

Nanoliposomes as nonviral vectors in cancer gene therapy.

Yildiz S, Entezari M, Paskeh M, Mirzaei S, Kalbasi A, Zabolian A MedComm (2020). 2024; 5(7):e583.

PMID: 38919334 PMC: 11199024. DOI: 10.1002/mco2.583.

References

Hu Y, Qiu Y, Yague E, Ji W, Liu J, Zhang J . miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer. Cell Death Dis. 2016; 7(6):e2291. PMC: 5108343. DOI: 10.1038/cddis.2016.194. View

Grelet S, Link L, Howley B, Obellianne C, Palanisamy V, Gangaraju V . A regulated PNUTS mRNA to lncRNA splice switch mediates EMT and tumour progression. Nat Cell Biol. 2017; 19(9):1105-1115. PMC: 5578890. DOI: 10.1038/ncb3595. View

Zhang P, Wang L, Rodriguez-Aguayo C, Yuan Y, Debeb B, Chen D . miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13. Nat Commun. 2014; 5:5671. PMC: 4377070. DOI: 10.1038/ncomms6671. View

Yang Y, Xun N, Wu J . Long non-coding RNA FGF14-AS2 represses proliferation, migration, invasion, and induces apoptosis in breast cancer by sponging miR-205-5p. Eur Rev Med Pharmacol Sci. 2019; 23(16):6971-6982. DOI: 10.26355/eurrev_201908_18737. View

Fan X, Chen W, Fu Z, Zeng L, Yin Y, Yuan H . MicroRNAs, a subpopulation of regulators, are involved in breast cancer progression through regulating breast cancer stem cells. Oncol Lett. 2017; 14(5):5069-5076. PMC: 5666663. DOI: 10.3892/ol.2017.6867. View

Du Y, Tu G, Yang G, Li G, Yang D, Lang L . MiR-205/YAP1 in Activated Fibroblasts of Breast Tumor Promotes VEGF-independent Angiogenesis through STAT3 Signaling. Theranostics. 2017; 7(16):3972-3988. PMC: 5667419. DOI: 10.7150/thno.18990. View

Markou A, Yousef G, Stathopoulos E, Georgoulias V, Lianidou E . Prognostic significance of metastasis-related microRNAs in early breast cancer patients with a long follow-up. Clin Chem. 2013; 60(1):197-205. DOI: 10.1373/clinchem.2013.210542. View

Sorlie T, Wang Y, Xiao C, Johnsen H, Naume B, Samaha R . Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics. 2006; 7:127. PMC: 1489944. DOI: 10.1186/1471-2164-7-127. View

Hamidi H, Pietila M, Ivaska J . The complexity of integrins in cancer and new scopes for therapeutic targeting. Br J Cancer. 2016; 115(9):1017-1023. PMC: 5117799. DOI: 10.1038/bjc.2016.312. View

10.

Qiu C, Huang F, Zhang Q, Chen W, Zhang H . miR-205-3p promotes proliferation and reduces apoptosis of breast cancer MCF-7 cells and is associated with poor prognosis of breast cancer patients. J Clin Lab Anal. 2019; 33(8):e22966. PMC: 6805278. DOI: 10.1002/jcla.22966. View

11.

Elgamal O, Park J, Gusev Y, Azevedo-Pouly A, Jiang J, Roopra A . Tumor suppressive function of mir-205 in breast cancer is linked to HMGB3 regulation. PLoS One. 2013; 8(10):e76402. PMC: 3788717. DOI: 10.1371/journal.pone.0076402. View

12.

Vallabhaneni K, Penfornis P, Xing F, Hassler Y, Adams K, Mo Y . Stromal cell extracellular vesicular cargo mediated regulation of breast cancer cell metastasis via ubiquitin conjugating enzyme E2 N pathway. Oncotarget. 2018; 8(66):109861-109876. PMC: 5746349. DOI: 10.18632/oncotarget.22371. View

13.

Xiao Y, Humphries B, Yang C, Wang Z . MiR-205 Dysregulations in Breast Cancer: The Complexity and Opportunities. Noncoding RNA. 2019; 5(4). PMC: 6958506. DOI: 10.3390/ncrna5040053. View

14.

Yilmaz M, Christofori G . EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009; 28(1-2):15-33. DOI: 10.1007/s10555-008-9169-0. View

15.

Baffa R, Fassan M, Volinia S, OHara B, Liu C, Palazzo J . MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol. 2009; 219(2):214-21. DOI: 10.1002/path.2586. View

16.

Shaker O, Maher M, Nassar Y, Morcos G, Gad Z . Role of microRNAs -29b-2, -155, -197 and -205 as diagnostic biomarkers in serum of breast cancer females. Gene. 2015; 560(1):77-82. DOI: 10.1016/j.gene.2015.01.062. View

17.

Avril-Sassen S, Goldstein L, Stingl J, Blenkiron C, Le Quesne J, Spiteri I . Characterisation of microRNA expression in post-natal mouse mammary gland development. BMC Genomics. 2009; 10:548. PMC: 2784809. DOI: 10.1186/1471-2164-10-548. View

18.

Iorio M, Ferracin M, Liu C, Veronese A, Spizzo R, Sabbioni S . MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65(16):7065-70. DOI: 10.1158/0008-5472.CAN-05-1783. View

19.

Lee J, Park M, Park J, Lee H, Shin D, Kang Y . Loss of the polycomb protein Mel-18 enhances the epithelial-mesenchymal transition by ZEB1 and ZEB2 expression through the downregulation of miR-205 in breast cancer. Oncogene. 2013; 33(10):1325-35. DOI: 10.1038/onc.2013.53. View

20.

Tetreault M, Yang Y, Katz J . Krüppel-like factors in cancer. Nat Rev Cancer. 2013; 13(10):701-13. DOI: 10.1038/nrc3582. View